Combination Vaccine Articles & Analysis
16 news found
By accurately detecting these variants, healthcare professionals and researchers can make informed decisions regarding public health measures, treatment options, and vaccine effectiveness. COVID-19 RT-qPCR Detection Kit Plus In addition to the COVID-19 Mutation RT-qPCR Detection Kit Alpha Delta Kappa, Alfa Chemistry has also introduced the COVID-19 RT-qPCR Detection Kit Plus. ...
Therefore, when the more transmissible Omicron BA.1 sublineage hit back in February, population immunity from infection was low. This, combined with a low vaccine coverage, led to a huge wave of both infections and deaths, especially amongst the elderly. Mainland China has very low levels of immunity across its population. Its citizens were ...
This study will look at participants immunised with two doses of Pfizer-BioNtech vaccine to be randomly allocated to receive either a: further full adult dose Pfizer-BioNTech vaccine one-third adult dose Pfizer-BioNTech vaccine full child dose Pfizer-BioNTech vaccine full dose Novavax vaccine meningitis ...
If successful, this trial may enable global authorizations, including in high income countries and LMICs. Data on mix-and-match combinations of vaccines – like those being assessed in this trial - will contribute to the design of flexible vaccination strategies aimed at controlling COVID-19 and combatting emerging SARS-CoV-2 variants. ...
ByVaxxinit
These changes are associated with increased infectivity and confer the potential to evade the host antibody immune response induced by previous vaccinations or infections (“escape mutations”). While Omicron is relatively less pathogenic than previous variants like Delta, it remains a lethal threat to those patients who cannot be vaccinated or have a ...
An oral COVID-19 vaccine would significantly improve vaccination logistics and reduce costs. ...
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa Oramed Pharmaceuticals Inc. ...
BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate. ...
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular ...
ByEnterome
(Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and ...
ByNovavax
” “In 2020, we initiated a Phase 1/2a clinical trial of the adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma. Both this study and our Phase 1/2a trial with EVX-01 remain on track and our other product candidates – EVX-03 for multiple cancer indications and EVX-B1, a vaccine for ...
Genano recommends equipping offices, restaurants, shops and other businesses with air purifiers to further protect their customers and staff. "The new coronavirus vaccine is fantastic news, but it will be a while still before everyone can be immunised. ...
Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax™ adjuvant, today announced a ...
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19 Oxford, UK, September 8: SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its partner the Serum Institute of ...
The contract could be worth up to $24 million over its eight-year term if all options are exercised. The vaccine combines BlueWillow’s novel intranasal NanoVax system with recombinant protective antigen (rPA) for anthrax from PBL. ...
Noble Awards $25,000 in Research Services to SynAm Vaccine Contributes Drug Development Services through InvestMaryland Business Competition Noble Life Sciences, Inc. ...